Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Alexandre TheocharidesHeinz GisslingerValerio De StefanoVincenzo AccursoAlessandra IurloTimothy DevosMiklos EgyedEric LippertRegina Garcia DelgadoNathan CantoniAnders E A DahmDamianos SotiropoulosErik HoutsmaAoife SmythAmir IqbalPaola Di MatteoMike ZuurmanPeter A W Te BoekhorstPublished in: European journal of haematology (2023)
This study demonstrates that ruxolitinib treatment in PV maintains durable hematocrit control with a decrease in the number of phlebotomies in the majority of patients and was generally well tolerated.